CN101511836A - 稠合的嘧啶并化合物 - Google Patents

稠合的嘧啶并化合物 Download PDF

Info

Publication number
CN101511836A
CN101511836A CNA2007800331017A CN200780033101A CN101511836A CN 101511836 A CN101511836 A CN 101511836A CN A2007800331017 A CNA2007800331017 A CN A2007800331017A CN 200780033101 A CN200780033101 A CN 200780033101A CN 101511836 A CN101511836 A CN 101511836A
Authority
CN
China
Prior art keywords
optional
replaces
alkyl
group
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800331017A
Other languages
English (en)
Chinese (zh)
Inventor
C·T·哈尔萨尔
D·A·拉奇
I·西姆普森
R·A·沃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101511836A publication Critical patent/CN101511836A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2007800331017A 2006-07-06 2007-07-05 稠合的嘧啶并化合物 Pending CN101511836A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81887806P 2006-07-06 2006-07-06
US60/818,878 2006-07-06

Publications (1)

Publication Number Publication Date
CN101511836A true CN101511836A (zh) 2009-08-19

Family

ID=38857945

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800331017A Pending CN101511836A (zh) 2006-07-06 2007-07-05 稠合的嘧啶并化合物

Country Status (19)

Country Link
US (1) US7709471B2 (https=)
EP (1) EP2046793A2 (https=)
JP (1) JP2009542613A (https=)
KR (1) KR20090038895A (https=)
CN (1) CN101511836A (https=)
AR (1) AR061850A1 (https=)
AU (1) AU2007270931A1 (https=)
BR (1) BRPI0714045A2 (https=)
CA (1) CA2656936A1 (https=)
CL (1) CL2007001973A1 (https=)
EC (1) ECSP099044A (https=)
IL (1) IL196207A0 (https=)
MX (1) MX2009000220A (https=)
NO (1) NO20090052L (https=)
RU (1) RU2009103810A (https=)
TW (1) TW200808325A (https=)
UY (1) UY30472A1 (https=)
WO (1) WO2008003958A2 (https=)
ZA (1) ZA200900073B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548994A (zh) * 2009-09-25 2012-07-04 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
CN102695700A (zh) * 2009-10-02 2012-09-26 贝林格尔.英格海姆国际有限公司 用作蛋白酪氨酸激酶2抑制剂的嘧啶衍生物
CN103492391A (zh) * 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
CN107949279A (zh) * 2015-07-06 2018-04-20 得克萨斯系统大学评议会 可用作用于治疗人类癌症的抗癌剂的苯甲酰胺或苯扎明化合物
CN113999244A (zh) * 2021-12-30 2022-02-01 北京鑫开元医药科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物及其制备方法
CN114392258A (zh) * 2021-12-30 2022-04-26 北京鑫开元医药科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物药物制剂及其制备方法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
EP2049500B1 (en) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
WO2008113711A1 (en) 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
WO2009042711A1 (en) * 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2205603B1 (en) 2007-09-28 2014-01-15 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
NZ586346A (en) 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
JP2011527667A (ja) 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
EP4585589A3 (en) * 2008-12-03 2025-11-19 The Scripps Research Institute Stem cell cultures
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
TWI399551B (zh) * 2009-06-26 2013-06-21 Senao Networks Inc Burner device and burner method
US20110218295A1 (en) * 2010-03-02 2011-09-08 Basf Se Anionic associative rheology modifiers
US8673275B2 (en) 2010-03-02 2014-03-18 Basf Se Block copolymers and their use
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
HRP20181272T1 (hr) 2013-11-13 2018-10-05 Vertex Pharmaceuticals Incorporated Postupci priprave inhibitora replikacije virusa influence
RS59144B1 (sr) 2013-11-13 2019-09-30 Vertex Pharma Inhibitori replikacije virusa influence
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
US11155556B2 (en) * 2016-04-07 2021-10-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders
CN115485025A (zh) * 2020-02-28 2022-12-16 雷密克斯医疗公司 用于调节剪接的化合物和方法
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
EP4157849A4 (en) * 2021-08-10 2024-12-11 Uppthera, Inc. NOVEL PLK1 DEGRADATION-INDUCING COMPOUND
WO2023034812A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1427730E (pt) 2001-09-04 2006-11-30 Boehringer Ingelheim Pharma Novas di-hidropteridinonas, processo para sua preparação e sua utilização como medicamento
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
BR0318145A (pt) 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
JP2008510771A (ja) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200804389A (en) 2006-02-14 2008-01-16 Vertex Pharma Dihydrodiazepines useful as inhibitors of protein kinases

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548994A (zh) * 2009-09-25 2012-07-04 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
CN103492391A (zh) * 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
CN102695700A (zh) * 2009-10-02 2012-09-26 贝林格尔.英格海姆国际有限公司 用作蛋白酪氨酸激酶2抑制剂的嘧啶衍生物
CN107949279A (zh) * 2015-07-06 2018-04-20 得克萨斯系统大学评议会 可用作用于治疗人类癌症的抗癌剂的苯甲酰胺或苯扎明化合物
US11548894B2 (en) 2015-07-06 2023-01-10 The Board Of Regents Of The University Of Texas System Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
CN113999244A (zh) * 2021-12-30 2022-02-01 北京鑫开元医药科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物及其制备方法
CN114392258A (zh) * 2021-12-30 2022-04-26 北京鑫开元医药科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物药物制剂及其制备方法
CN114392258B (zh) * 2021-12-30 2024-04-16 北京朗瑞邦科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物药物制剂及其制备方法

Also Published As

Publication number Publication date
WO2008003958A3 (en) 2008-03-06
ZA200900073B (en) 2010-06-30
US7709471B2 (en) 2010-05-04
US20080009482A1 (en) 2008-01-10
EP2046793A2 (en) 2009-04-15
KR20090038895A (ko) 2009-04-21
UY30472A1 (es) 2008-02-29
JP2009542613A (ja) 2009-12-03
TW200808325A (en) 2008-02-16
AR061850A1 (es) 2008-09-24
IL196207A0 (en) 2009-09-22
AU2007270931A1 (en) 2008-01-10
CL2007001973A1 (es) 2008-04-04
CA2656936A1 (en) 2008-01-10
BRPI0714045A2 (pt) 2012-12-11
RU2009103810A (ru) 2010-08-20
MX2009000220A (es) 2009-01-22
WO2008003958A2 (en) 2008-01-10
NO20090052L (no) 2009-01-28
ECSP099044A (es) 2009-02-27

Similar Documents

Publication Publication Date Title
CN101511836A (zh) 稠合的嘧啶并化合物
JP7550174B2 (ja) 新規化合物及び疾患の治療のためのその医薬組成物
AU2010271270B2 (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
EP3596073B1 (en) Tricyclic compounds for use in treatment of proliferative disorders.
JP2024519170A (ja) 化合物
JP5529761B2 (ja) プロテイン・キナーゼ阻害剤とその利用法
JP6294953B2 (ja) Ｐ２ｘ７調節物質
CN102388048B (zh) 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途
ES2339174T3 (es) N-(aril- o heteroaril)-pirazo(1,5-a)pirimidinas 3-sustituidas como inhibidores de cinasa.
BR112020025202A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de doenças
MX2008016203A (es) Ciclopenta [d] pirimidinas como inhibidores de la proteina cinasa akt.
JP7462951B2 (ja) Ｊａｋ阻害剤
BRPI0807868A2 (pt) Composto ou um sal farmaceuticamente aceitável ou n-óxido do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável ou n-óxido, método para o tratamento de um ser humano ou animal que sofre um câncer, e, processo para preparar um composto ou um sal farmaceuticamente aceitável ou n-óxido do mesmo
CN101448830A (zh) 作为抗增殖剂的二氢碟啶化合物
DK2588480T3 (en) 3,4-dihydro-pyrrolo [1,2-a] pyrazine-2,8 (1H) -DICARBOXAMIDDERIVATER PREPARATION AND THERAPEUTIC USE THEREOF
EP4612148A1 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
AU2015201984A1 (en) SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
HK1129888A1 (en) 6,7,8,9-tetrahydro-5h-pyrimido[4,5-d]azepin-4-yl]-amine derivatives as modulators of trpv1 for the treatment of pain
HK1129888B (en) 6,7,8,9-tetrahydro-5h-pyrimido[4,5-d]azepin-4-yl]-amine derivatives as modulators of trpv1 for the treatment of pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090819